tldrdailynews.com logo

Eli Lilly's forforglipron Success Spurs Global Obesity and Diabetes Treatment Approvals

1 min read
Source: Financial Times
Eli Lilly's forforglipron Success Spurs Global Obesity and Diabetes Treatment Approvals
Photo: Financial Times
TL;DR

Eli Lilly announced that its anti-obesity pill, orforglipron, successfully met weight-loss targets in a key diabetes trial, reducing body weight by 10.5% on average, which boosts its plans for FDA approval and intensifies competition with Novo Nordisk in the weight-loss drug market.

Topics:top-newshealth#diabetes#eli-lilly#health#market-competition#trial-results#weight-loss-pill
Share this article
  1. Eli Lilly’s weight-loss pill meets target in key diabetes trial  Financial Times
  2. Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval  CNBC
  3. Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity  Eli Lilly and Company
  4. Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals  The Wall Street Journal
  5. Eli Lilly's oral GLP-1 pill may help people with Type 2 diabetes lose 'significant' weight, study finds  ABC News

Want the full story? Read the original reporting

Read on Financial Times